Published

Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses

Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.

Open source BibTeX RIS

Bibliographic context

Journal: The Transmitter
Date: 2022-12-31
Source: OpenAlex
DOI: 10.53053/nbdr8957
PubMed: Unavailable

Authors

Peter Hess

Watch author

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses2022-12-31

Related papers

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depressionTrials · 2024-07-02 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-18 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary Clinical Trials · 2022-11-01